Revenue YoY
—
Operating Income YoY
-75.68%
Net Income YoY
-96.70%
Net Margin Δ
—
Net income bridge for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: −$674.20M-96.70%
Profit bridge breakdown for Revolution Medicines (RVMD) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | −$697.51M | — |
| Revenue | $0.00 | 0.0% |
| Cost of Revenue | −$9.24M | -1.4% |
| Operating Expenses | −$588.17M | -87.2% |
| Other Income / Expense | −$76.04M | -11.3% |
| Income Tax | −$753.00K | -0.1% |
| Net Loss | −$1.37B | — |
- Prior Net Income−$697.51M
- Revenue$0.00
- Cost of Revenue−$9.24M
- Operating Expenses−$588.17M
- Other Income / Expense−$76.04M
- Income Tax−$753.00K
- Net Loss−$1.37B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement